US in vitro diagnostics (IVD) industry struggling against odds
This article was originally published in Clinica
Executive Summary
Striking the right balance between regulation and protecting public health is no easy task, Jim Benson, senior vice-president of US trade association HIMA, cautioned Chinese clinical laboratory managers and regulators. Addressing the Sino-American Conference on Clinical Laboratory Management in Beijing last week, he outlined some of the problems facing the $8 billion US IVD industry today - some 30 years after regulations were first put in place.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.